Browse > Article
http://dx.doi.org/10.5762/KAIS.2019.20.9.306

Generation of a transgenic pig expressing human dipeptidylpeptidase-4 (DPP-4)  

Chung, Hak Jae (Swine Science Division, National Institute of Animal Science, Rural Development Administration)
Sa, Soo Jin (Swine Science Division, National Institute of Animal Science, Rural Development Administration)
Baek, Sun Young (Swine Science Division, National Institute of Animal Science, Rural Development Administration)
Cho, Eun Suek (Swine Science Division, National Institute of Animal Science, Rural Development Administration)
Kim, Young Shin (Swine Science Division, National Institute of Animal Science, Rural Development Administration)
Hong, Jun Ki (Swine Science Division, National Institute of Animal Science, Rural Development Administration)
Cho, Kyu Ho (Swine Science Division, National Institute of Animal Science, Rural Development Administration)
Kim, Ji Youn (Animal Biotechnology Division, National Institute of Animal Science, Rural Development Administration)
Park, Mi Ryung (Animal Biotechnology Division, National Institute of Animal Science, Rural Development Administration)
Kim, Kyung Woon (Planning & Coordination Division, National Institute of Animal Science, Rural Development Administration)
Publication Information
Journal of the Korea Academia-Industrial cooperation Society / v.20, no.9, 2019 , pp. 306-314 More about this Journal
Abstract
As dipeptidyl peptidase-4(DPP-4) inhibitors are used widely as a secondary treatment for type 2 diabetes because they tend to be well tolerated with minimal side effects, the human DPP-4(hDPP-4) gene was injected into a pig zygote through micro-injection, and 1-cell stage fertilized embryos were then transplanted surgically into the oviduct. Three pigs were fertilized with hDPP-4 genes and produced sixteen piglets, in which one male piglet was identified to be transgenic. Finally, transgenic pigs showing hDPP-4 gene expression in the tail were produced. Western blot and RT-PCR analysis confirmed that the hDPP-4 is expressed strongly in the membrane cells of the transgenic pig, and that the hDPP-4 gene appears in various tissues and tails. This suggests that the expression vector is normally expressed in transgenic pigs. These results are anticipated to be a model animal to check the endocrine function for insulin resistance that occurs in a hDPP-4 transgenic pig and to increase its value for use as a material in newly developed medicines.
Keywords
Insulin-Resistant; Dipeptidylpeptidase-4(DPP-4); Micro-Injection; Transgenic; Pig; Gene-Expression;
Citations & Related Records
연도 인용수 순위
  • Reference
1 H. C. Lee, H. M. Kim, S. Lee, K. B. Oh, H. J. Chung, B. C. Yang, K. W. Kim, P. Lee, J. K. Park, W. K. Chang. "Production of a Transgenic Pig Overexpressing Phosphoprotein Enriched in Astrocytes 15 (PEA 15)", Reproductive & Developmental Biology, vol. 35, pp. 239-245. 2011.
2 H. G. Lee, H. C. Lee, S. W. Kim, P. Lee, H. J. Chung, Y. K. Lee, J. H. Han, I. S. Hwang, J. I. Yoo, Y. K. Kim, H. T. Kim, H. T. Lee, W. K. Chang, J. K. Park. "Production of recombinant human von Willebrand factor in the milk of transgenic pigs", Journal of Reproduction and Development, vol. 55, pp. 484-490. 2009. DOI: http://dx.doi.org/10.1262/jrd.20212   DOI
3 L. D. Itz, F. Ishikawa, D. L. Greiner. "Humanized mice in translation biomedical research", Nature Reviews Immunology, vol. 7, pp. 118-130. 2007.   DOI
4 I. H. Drespe, G. K. Polzhofer, A. S. Turner, Grauer JN. "Animal models for spinal fusion", The Spine Journal, vol. 5, pp. S209-S216. 2005. DOI: http://dx.doi.org/10.1016/j.spinee.2005.02.013   DOI
5 J. K. Lunney. "Advances in swine biomedical model genomics", International Journal of Biological Sciences, vol. 3, pp. 179-184. 2007. DOI: http://dx.doi.org/10.7150/ijbs.3.179   DOI
6 S. E. Kahn, R. L. Hull, K. M. Utzschneider. "Mechanisms linking obesity to insulin resistance and type 2 diabetes", Nature, vol. 444, pp. 840-846. 2006. DOI: http://dx.doi.org/10.1038/nature05482   DOI
7 G. Kloppel, M. Lohr, K. Habich, M. Oberholzer, P. U. Heitz. "Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited", Survey and Synthesis of Pathology Resesrch, vol.4, pp. 110-125. 1985.
8 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. "Report of the expert committee on the diagnosis and classification of diabetes mellitus", Diabetes Care, vol. 26, pp. S5-S20. 2003.   DOI
9 M. A. Nauck, E. Homberger, E. G. Siegel, R. C. Allen, R. P. Eaton, R. Ebert, W. Creutzfeldt. "Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses", The Journal of Clinical Endocrinology and Metabolism, vol. 63, pp. 492-498. 1986. DOI: http://dx.doi.org/10.1210/jcem-63-2-492   DOI
10 J. P. Despres, I. Lemieux. "Abdominal obesity and metabolic syndrome", Nature, vol. 444, pp. 881-887. 2006. DOI: http://dx.doi.org/10.1038/nature05488   DOI
11 D. J. Drucker. "The biology of incretin hormones", Cell Metabolism, vol. 3, pp. 153-165. 2006. DOI: http://dx.doi.org/10.1016/j.cmet.2006.01.004   DOI
12 J. R. Ussher, D. J. Drucker. "Cardiovascular biology of the incretin system", Endocrine Reviews, vol. 33, pp. 187-215. 2012. DOI: http://dx.doi.org/10.1210/er.2011-1052   DOI
13 R. Yazbeck, G. S. Howarth, C. A. Abbott. "Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?", Trends in Pharmacological Sciences, vol. 30, pp. 600-607. 2009. DOI: http://dx.doi.org/10.1016/j.tips.2009.08.003   DOI
14 S. Blech, E. Ludwig-Schwellinger, E. U. Grafe-Mody, B. Withopf, K. Wagner. "The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans", Drug Metabolism and Disposition, vol. 38, pp. 667-678. 2010. DOI: http://dx.doi.org/10.1124/dmd.109.031476   DOI
15 N. Matikainen, S. Mänttäri, A. Schweizer, A. Ulvestad, D. Mills, B. E. Dunning, J. E. Foley, M. R. Taskinen. "Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes", Diabetologia, vol. 49, pp. 2049-2057. 2006. DOI: http://dx.doi.org/10.1007/s00125-006-0340-2   DOI
16 A. J. Scheen, G. Charpentier, C. J. Ostgren, A. Hellqvist, I. Gause-Nilsson. "Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus", Diabetes Metabolism Research and Reviews, vol. 26, pp. 540-549. 2010. DOI: http://dx.doi.org/10.1002/dmrr.1114   DOI
17 E. J. Rhee, W. Y. Lee, K. W. Min, V. K. Shivane, A. R. Sosale, H. C. Jang, C. H. Chung, I. S. Nam-Goong, J. A. Kim, S. W. Kim; Gemigliptin Study 006 Group. "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone", Diabetes Obesity and Metabolism, vol. 15, pp. 523-530. 2013. DOI: http://dx.doi.org/10.1111/dom.12060   DOI
18 Y. L. He, R. Sabo, J. Campestrini, Y. Wang, M. Ligueros-Saylan, K. C. Lasseter, S. C. Dilzer, D. Howard, W. P. Dole. "The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin", European Journal Clinical Pharmacology, vol. 63, pp. 677-686. 2007.   DOI
19 B. Eliasson, D. Möller-Goede, K. Eeg-Olofsson, C. Wilson, J. Cederholm, P. Fleck, M. Diamant, M. R. Taskinen, U. Smith. "Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomized double-blind placebo-controlled study", Diabetologia, vol. 55, pp. 915-925. 2012. DOI: http://dx.doi.org/10.1007/s00125-011-2447-3   DOI